7 news items
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
IVVD
7 May 24
be a highly attractive option to alter the course of established infection. "It's important to remember that SARS-CoV-2 still poses a major
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
IVVD
15 Apr 24
assays against major SARS-CoV-2 variants, including JN.1, the dominant variant in the U.S. currently according to estimates from the Centers for Disease
Invivyd Announces CEO Transition
IVVD
12 Apr 24
-like particle and authentic virus neutralization assays against major SARS-CoV-2 variants, including JN.1, the dominant variant in the U.S. currently
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
IVVD
4 Apr 24
-like particle and authentic virus neutralization assays against major SARS-CoV-2 variants, including JN.1, the dominant variant in the U.S. currently
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
IVVD
22 Mar 24
of VYD222 against major SARS-CoV-2 variants; the company's mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable
i26o5lr0ibqwf4mz9ct0uyayrq6orkj6pa5s7jr48i56i3uys
IVVD
22 Mar 24
with ongoing in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1PEMGARDA is the first PrEP monoclonal antibody
f86f exk544mr1yjmp7pnyrt1sb3h4
IVVD
22 Mar 24
against major SARS-CoV-2 variants, including JN.1PEMGARDA is the first PrEP monoclonal antibody (mAb) to receive EUA from the U.S. FDA
- Prev
- 1
- Next